{
    "clinical_study": {
        "@rank": "102729", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give an anti-HIV drug\n      combination containing indinavir and ritonavir to HIV-positive patients who have failed\n      previous treatment with protease inhibitors."
        }, 
        "brief_title": "Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive indinavir and ritonavir twice daily plus 2 NRTIs (NRTIs are not provided by\n      this study). Physical examinations and laboratory tests, including plasma viral RNA levels\n      and CD4 cell counts, are performed at Day 1 and Weeks 4, 8, 12, 16, 20, and 24 (or at\n      discontinuation). The incidence of serious and drug-related adverse experiences is tabulated\n      to determine drug safety. The proportion of patients achieving plasma viral RNA levels below\n      50 copies/ml (by UltraSensitive assay) are estimated statistically to determine drug\n      efficacy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive.\n\n          -  Have a viral load (level of HIV in the blood) of 2500 copies/ml or greater within 45\n             days of study entry.\n\n          -  Have a CD4 cell count of 100 cells/mm3 or greater within 45 days of study entry.\n\n          -  Have been on an anti-HIV drug regimen containing a protease inhibitor for at least 16\n             weeks and initially did well on this treatment (your viral load decreased\n             significantly) but later experienced treatment failure on this drug combination (your\n             viral load increased significantly).\n\n          -  Experienced treatment failure within 24 weeks of study entry.\n\n          -  Are 18 years of age or older.\n\n          -  Agree to use effective barrier methods of birth control (such as condoms) during the\n             study.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Are allergic to ritonavir or indinavir.\n\n          -  Have hepatitis.\n\n          -  Have an abnormal chest x-ray or abnormal liver function tests.\n\n          -  Have taken 2 protease inhibitors at the same time for 7 or more days.\n\n          -  Have taken non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the 2 weeks\n             before study entry.\n\n          -  Have a medical condition that might make it unsafe for you to take the study drugs.\n\n          -  Have experienced resistance to NRTIs and no new NRTI therapy is possible.\n\n          -  Have taken certain medications.\n\n          -  Abuse alcohol or drugs.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002361", 
            "org_study_id": "246S", 
            "secondary_id": "088-00"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Indinavir", 
                "Ritonavir", 
                "HIV Protease Inhibitors", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "Indinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "LAC / USC Med Ctr / Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / Div of Infect Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Chase Braxton Health Service"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12208"
                    }, 
                    "name": "Albany Med College"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ of North Carolina / Infectious Disease Division"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "The Research and Education Group"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Open-Label, 24-Week Study to Evaluate the Safety and Activity of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 200 Mg b.i.d. and Two NRTIs in HIV-1 Infected Patients Who Failed PI Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002361"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2000"
    }, 
    "geocoordinates": {
        "Albany Med College": "42.653 -73.756", 
        "Beth Israel Deaconess Med Ctr": "42.358 -71.06", 
        "Chase Braxton Health Service": "39.29 -76.612", 
        "LAC / USC Med Ctr / Infectious Diseases": "34.052 -118.244", 
        "Northwestern Univ / Div of Infect Diseases": "41.878 -87.63", 
        "The Research and Education Group": "45.523 -122.676", 
        "Univ of Miami School of Medicine": "25.789 -80.226", 
        "Univ of North Carolina / Infectious Disease Division": "35.913 -79.056"
    }
}